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AbsTRACT
The newly recognised and emerging fungal species, 
Candida auris, has caused worldwide invasive infections 
and has been implicated in difficult to control hospital 
outbreaks. Challenges are encountered in the correct 
identification of this fungus as commonly used 
phenotypic and biochemical methods fail to differentiate 
C. auris from other Candida species. Its resistance profile, 
over 90% of isolates are fluconazole resistant and 
35% are resistant to amphotericin, confronts clinicians 
with the restricted arsenal of antifungals and concerns 
about optimal treatment. The very first C. auris isolate 
was recovered from a paediatric patient in retrospect. 
Although infections with the more antifungal-resistant 
Candida species are less frequently observed in 
paediatric patients, this seems to be different for C. auris 
infections.
InTRoduCTIon
The emergence of Candida auris has received 
worldwide attention, not only from the scien-
tific and clinical communities, but has as well 
been picked up by several public media channels. 
C. auris being reported as a ‘sometimes deadly 
and often resistant fungal infection’, ‘a superbug 
highly resistant to traditional drugs’ and ‘C. auris 
sickens dozens’, makes clear that there is some-
thing to be feared from this newly recognised 
Candida species.
The yeast C. auris was described for the first 
time in 2009 on recovery from the external ear 
canal of a Japanese patient.1 Subsequently, C. auris 
was recognised as causing chronic otitis media in 
15 patients in Korea, including three paediatric 
patients.2 The earliest case to date was identified in 
retrospect by DNA sequencing of a Korean blood-
stream isolate from a paediatric surgery patient in 
1996.3 Since 2009, patients colonised and infected 
with C. auris have been reported from nearly all 
continents (except for Australia and Antarctica). C. 
auris has been shown to be a challenge to identify 
and treat, is capable to cause difficult to manage 
hospital outbreaks and reasons for its emergence is 
far from clear.4 5
The vast majority of infections caused by 
Candida species in the paediatric population are 
caused by C. albicans or C. parapsilosis, while the 
more antifungal resistant species as C. glabrata 
and C. krusei are less prevalent in comparison to 
Candida infections in adult patients.6 7 As the very 
first reports of C. auris infections are described in 
both neonates and children as well as adults, atten-
tion needs to be paid to its consequences for the 
management of Candida infections in the paedi-
atric population.
ClInICAl epIdemIology
A literature search, restricted to publica-
tions in English, including publications up to 
8 December 2017, was performed by using Medline/
Pubmed. At that moment, published clinical reports 
of C. auris infections originated from Japan, South 
Korea, India, Kuwait, Oman, South Africa, Vene-
zuela, Panama, Colombia, Pakistan, Israel, Spain, 
UK, Canada and the USA describing 109 patients 
with candidaemia, 19 patients with chronic otitis 
media or otitis externa and 28 patients with other 
infections (including candiduria/urinary tract infec-
tions (n=16) and wound and soft tissue infections 
(n=6)).1–4 8–21 Real-time data from the Centers for 
Disease Control and Prevention show that new 
cases are reported on an almost weekly basis with 
a total of 243 clinical cases of C. auris infection in 
the USA.22 Public Health England shows a more 
episodic pattern in reported clinical cases (56 in 
total) with high increases during outbreaks.23 No 
paediatric patients have been reported in the UK 
(Dr E M Johnson, Public Health England, personal 
communication).
Ten out of the 18 publications described infec-
tions in adult patients only. Two publications did 
include paediatric patients but no details were 
given separately for the patients <18 years of 
age19 21 or age was not mentioned.13 Twenty-three 
paediatric patients have been reported in five case 
series published, of which 20 neonates and children 
suffered from a blood stream infection (18% of 
the total population).3 8 9 12 Three other paediatric 
patients suffered from chronic otitis media with 
positive ear swabs for C. auris.2 Table 1 summarises 
the clinical characteristics of those infections. Paedi-
atric patients have only been reported in Asia and 
South America. Underlying conditions and risk 
factors are comparable to those known to render 
paediatric patients at risk for developing candi-
daemia and invasive candidiasis. Of the 20 paedi-
atric patients with candidaemia due to C. auris, 
14 were neonates and/or born prematurely. Older 
infants and children developed C. auris candi-
daemia during intensive care unit (ICU) admissions, 
postsurgery or with an underlying haematological 
malignancy. Antifungal regimens prescribed varied 
hugely with half of the patients receiving combi-
nation antifungal therapy with two or three anti-
fungals. Mortality was 30% in paediatric patients 
with C. auris blood stream infections and lower 
compared with adult patients with mortality rates 
ranging from 30% to 60%. In contrast, during 
the C. auris outbreak in a large UK hospital, no 
attributable deaths were observed due to C. auris 
infections.4
As C. auris has been commonly misidentified as 
Candida haemulonii, a rare encountered Candida 
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species causing invasive infections.3 8 10 11 13 Paediatric patients 
with C. haemulonii blood stream infections reported in the liter-
ature have been summarised in table 2. The clinical characteris-
tics are comparable to those described for C. auris fungaemia and 
neonates and children with well-known underlying conditions 
and risk factors to develop invasive fungal disease are affected. 
Thirteen paediatric patients from Kuwait, Korea and Brazil have 
been described, including five premature neonates.2 24–26 C. 
haemulonii infections have been more often described in infants 
and children (62%) compared with C. auris infections affecting 
mostly neonates (70%). Half of the patients with C. haemulonii 
infections were treated with combination antifungal therapy and 
the mortality rate was 30%.
Due to the low numbers of paediatric patients described, it is 
difficult to draw meaningful comparisons with Candida infec-
tions caused by other species, specific patient groups affected, 
geographic patterns and the outcome of the infections.
IdenTIfICATIon And susCepTIbIlITy
C. auris isolates have been misidentified as a range of other 
Candida species by using conventional phenotypic and 
biochemical methods. Most commonly, these isolates have been 
misidentified as C. haemulonii, as C. auris is phylogenetically 
closely related to the C. haemulonii species complex.3 8 10 11 13 
C. haemulonii complex species are less frequently detected 
than C. auris, although inaccuracies with the molecular iden-
tification of less common Candida species prevents a robust 
insight into these infections.5 It is also possible that some of 
the reported isolates of C. haemulonii are misidentified as C. 
auris. It has been suggested that chromogenic agar is a low-cost 
method to differentiate between C. auris and C. haemulonii 
isolates.5 Molecular techniques are recommended to identify C. 
auris to the species level. Matrix-assisted laser desorption ioni-
sation–time of flight mass spectrometry is capable of providing 
an accurate identification to the species level once spectra for 
C. auris are present in its database.5 The development of C. 
auris-specific PCR assays allows for rapid identification and 
are of particular use during outbreak settings.5 Sequencing 
of genetic loci and internal transcribed spacer domains of the 
rRNA provides the ability to differentiate between geographic 
clades.5 21 Genome sequencing has been shown to be useful in 
the identification of C. auris but is often not an available tech-
nique in most laboratories and is less feasible for routine iden-
tification purposes.
Table 1 Clinical epidemiology of published paediatric cases with Candida auris infections
patient number 
(reference) Country sex/age underlying condition
positive 
cultures
localisation of 
infection Treatment outcome
1 (Lee et al3) South Korea F/1 year Traumatic respiratory arrest
Aspiration pneumonia
Blood Blood stream FLU, removal CVC Survived
2 (Chowdhary et al8) India F/3 days Prematuritas, TEF, ICH, bacterial sepsis Blood Blood stream Caspo Died
3 (Chowdhary et al8) India F/10 days Prematuritas, ELBW, bacterial sepsis Blood Blood stream d-AmB Survived
4 (Chowdhary et al8) India F/28 days Pneumonia, late-onset sepsis Blood Blood stream d-AmB Survived
5 (Chowdhary et al8) India F/45 days Meningitis, septic shock, cardiac defect Blood Blood stream d-AmB Survived
6 (Chowdhary et al8) India M/10 years ALL, chronic kidney disease Blood Blood stream none Died
7 (Chowdhary et al9) India M/2 years Short-bowel syndrome, intestinal 
perforation, pneumonia, bacterial sepsis
Blood,
tip CVC
Blood stream FLU, d-AmB, removal 
CVC
Survived
8 (Calvo et al12) Venezuela F/30 days Prematuritas, sepsis Blood Blood stream AmB, VORI Died
9 (Calvo et al12 Venezuela F/13 days Prematuritas, colon atresia, sepsis, 
abdominal surgery
Blood Blood stream VORI, AmB, Caspo Died
10 (Calvo et al12) Venezuela M/17 days Abdominal surgery, sepsis Blood Blood stream FLU Died
11 (Calvo et al12) Venezuela F/23 days Prematuritas, septic shock Blood Blood stream Caspo Survived
12 (Calvo et al12) Venezuela M/18 days Prematuritas, sepsis Blood Blood stream FLU, VORI, Caspo Died
13 (Calvo et al12) Venezuela M/2 days Intestinal atresia, congenital heart 
disease, abdominal surgery
Blood Blood stream Caspo Survived
14 (Calvo et al12) Venezuela M/12 days NEC, HIE, sepsis, abdominal surgery Blood Blood stream VORI, Caspo Survived
15 (Calvo et al12) Venezuela M/11 days Prematuritas, NEC, sepsis, abdominal 
surgery
Blood Blood stream AmB, Caspo Survived
16 (Calvo et al12) Venezuela F/18 days Prematuritas, abdominal wall defect, 
sepsis, abdominal surgery
Blood Blood stream VORI Survived
17 (Calvo et al12) Venezuela F/14 years Septic shock Blood Blood stream VORI, Anidula, Caspo Survived
18 (Calvo et al12) Venezuela F/10 days Prematuritas, HIE, sepsis Blood Blood stream FLU Survived
19 (Calvo et al12) Venezuela F/2 months Meningocele, congenital hydrocephalus, 
sepsis
Blood Blood stream VORI, Caspo Survived
20 (Calvo et al12) Venezuela M/1 month Prematuritas, RDS, sepsis Blood Blood stream VORI, Caspo Survived
21 (Kim et al2) Korea Not 
available 
Chronic otitis media Ear Ear n.a. Survived
22 (Kim et al2) Korea Not 
available 
Chronic otitis media Ear Ear n.a. Survived
23 (Kim et al2) Korea Not 
available 
Chronic otitis media Ear Ear n.a. Survived
ALL, acute lymphoblastic leukaemia; AmB, amphotericin B; anidula, anidulafungin; caspo, caspofungin; CVC, central vascular catheter; d-AMB, amphotericin deoxycholate; ELBW, 
extreme low-birth weight; HIE, hypoxic ischaemic encephalopathy; ICH, intracerebral haemorrhage; FLU, fluconazole; NEC, necrotising enterocolitis; RDS, respiratory distress 
syndrome; TEF, trachea o esophageal fistula; VORI, voriconazole. 
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Intrinsic susceptibility patterns for C. auris show elevated 
minimum inhibitory concentrations for all three classes of anti-
fungals, the polyenes, the azoles and the echinocandins.27 Exact 
breakpoints as have been established for the common Candida 
species using the Clinical and Laboratory Standards Institute and 
the European Committee on Antimicrobial Susceptibility Testing 
methodologies have not been established.28 Antifungal suscepti-
bility data for 54 C. auris isolates showed that 93% were resis-
tant to fluconazole (≥32 mg/L), 54% to voriconazole (≥2 mg/L), 
35% to amphotericin B (≥2 mg/L) and 7% to echinocandins 
(≥8 mg/L).3 Forty-one per cent of those isolates were resistant 
to greater than or equal to two classes of antifungals. Resistance 
to all three classes of antifungals was observed in two Indian 
isolates.21 Of the 13 C. haemulonii infections in paediatric 
patients, eight isolates (62%) showed amphotericin B resistance, 
two isolates (15%) showed resistance for fluconazole and two 
(15%) for echinocandins.2 24–26
emeRgenCe of C. auris
Results from whole-genome sequencing studies suggest that C. 
auris has emerged near simultaneously in four or more locations 
rather than spreading from a single source.21 Sequencing of C. 
auris isolates in the UK have clearly shown that those isolates 
have several geographic origins and belong to at least three 
different clades.29 This suggest that C. auris isolates have been 
introduced into the UK from different locations.
But what has driven the emergence of this new Candida 
species? One of the explanations could be that C. auris has just 
not been recognised before, but this is not supported by retro-
spective reviews of large collections of Candida isolates. A thor-
ough review of over 15 000 Candida isolates from four continents 
(SENTRY isolate collection) did not detect any C. auris isolate 
before 2009.21 Increasing antifungal selection pressures either in 
humans and/or animals and/or the environment may cause the 
emergence of a new multidrug-resistant Candida species. The 
availability of antifungals with an improved toxicity profile has 
contributed to an expansion in the prescriptions of antifungals 
for prophylactic and empirical use. Increased antifungal use in 
agriculture and in the clinical environment has led to well-rec-
ognised emerging resistance among Aspergillus fumigatus 
(azole resistance) and C. glabrata (echinocandin resistance).30 
However, selection by antifungal pressure alone seems to be 
less likely as non-albicans Candida species have been increasing 
since the introduction of fluconazole in 1990. Changes to the 
ecological niches of C. auris and intrinsic characteristics as 
numerous virulence attributes, thermotolerance and salt toler-
ance and aggregation into difficult-to-disperse clusters, may have 
allowed the emergence of this newly recognised species causing 
human infections and persistence in hospital environments.31 A 
number of molecular resistance mechanisms are well described 
for causing resistance to particular antifungals in several Candida 
species.28 As yet, molecular mechanisms resulting in antifungal 
resistance in C. auris need to be elucidated.
ClInICAl mAnAgemenT
Based on susceptibility data, echinocandins seem to be the drug 
of choice as less than 10% resistance is reported.27 28 Micafungin 
showed increased efficacy in a murine study of C. auris candi-
daemia compared with fluconazole and amphotericin B.32 For 
the paediatric population, micafungin and caspofungin can be 
used while awaiting susceptibility testing results.33 34 Depending 
on the site of infection, alternative choices might be consid-
ered.5 28 33 34 Echinocandins have limited penetration in the 
cerebrospinal fluid and urine, and therefore other antifungal 
compounds should be used to treat central nervous system or 
renal tract infections.35 No recommendations can be made with 
regard to treatment with combinations of antifungals, as data are 
not available.
Consideration should be given to determine Candida isolates 
from mucosal surfaces and non-sterile sites to the species level 
and perform susceptibility testing. Particularly, in paediatric 
patients at high risk for developing invasive Candida infec-
tions, as these results may guide early and targeted treatment 
if a Candida infection is suspected based on clinical signs and 
symptoms. Even more so in premature neonates where a high 
percentage of false-negative blood cultures for Candida species 
has been described.36
An additional reason to be informed about colonising C. auris 
isolates in intensive care settings is to prevent transmission and to 
instal proper infection prevention and control measures. Several 
countries including the UK have released guidance documents 
with recommendations regarding screening policies, isolation 
Table 2 Clinical epidemiology of published paediatric cases with fungaemia caused by Candida haemulonii and Candida pseudohaemulonii
patient number 
(reference) Country sex/age underlying condition Candida species Treatment outcome
1 (Khan et al24) Kuwait M/6 weeks Prematuritas, hernia diaphragmatica C. haemulonii L-AmB, Caspo, FLU Died
2 (Khan et al24) Kuwait M/10 weeks Prematuritas, ELBW C. haemulonii FLU Survived
3 (Khan et al24) Kuwait F/7 weeks Prematuritas, ELBW C. haemulonii d-AmB, Caspo Survived
4 (Khan et al24) Kuwait F/1 month Prematuritas, LBW C. haemulonii L-AmB Died
5 (Kim et al2) Korea M/10 years Nasopharyngeal cancer, upper 
gastrointestinal bleeding
C. haemulonii ITRA, d-AmB, FLU Survived
6 (Kim et al2) Korea M/10 months Necrotising enterocolitis C. pseudohaemulonii FLU Survived
7 (Kim et al2) Korea M/2 years Acquired combined immunodeficiency C. pseudohaemulonii d-AmB Died
8 (Kim et al2) Korea F/2 months Necrotising enterocolitis C. pseudohaemulonii FLU, d-AmB, L-AmB Survived
9 (Kim et al2) Korea F/12 months Cardiac defect C. pseudohaemulonii L-AmB, FLU Died
10 (Kim et al2) Korea F/2 years Cardiac defect C. pseudohaemulonii FLU Survived
11 (Muro et al25) Brazil F/19 months Down syndrome, cardiac surgery, 
chylothorax
C. haemulonii d-AmB, L-AmB, FLU Survived
12 (Muro et al25) Brazil F/9 years Ewing’s sarcoma, febrile neutropaenia C. haemulonii d-AmB Survived
13 (Silva et al26) Brazil F/3 weeks Prematuritas, ELBW C. haemulonii FLU Survived
Caspo, caspofungin; d-AMB, amphotericin deoxycholate; ELBW, extreme low birth weight; FLU, fluconazole; L-AmB, liposomal amphotericin B; LBW, low birth weight; ITRA, 
itraconazole.
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of patients, contact precautions and cleaning of equipment and 
clinical environments.5 21
summARy
C. auris infections have emerged as an important challenge 
in the management of already vulnerable paediatric patients 
including premature neonates, infants and children admitted 
to ICUs and those with underlying malignancies. Proper iden-
tification is challenging with conventional methodologies 
failing. Great concern exists how to control this emerging new 
Candida species showing multidrug resistance and being very 
well capable to persist in hospital environments. The increased 
number of cases detected worldwide is causing a global concern 
and research is urgently needed. Current research is addressing 
the many unanswered questions related to the emergence of this 
Candida species, its molecular resistance and virulence mecha-
nisms and improved management options to minimise its impact 
on patient outcomes.
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